These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Dmitrieva N; Yu L; Viapiano M; Cripe TP; Chiocca EA; Glorioso JC; Kaur B Clin Cancer Res; 2011 Mar; 17(6):1362-72. PubMed ID: 21177410 [TBL] [Abstract][Full Text] [Related]
3. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209 [TBL] [Abstract][Full Text] [Related]
4. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235 [TBL] [Abstract][Full Text] [Related]
5. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583 [TBL] [Abstract][Full Text] [Related]
7. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862 [TBL] [Abstract][Full Text] [Related]
8. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
9. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049 [TBL] [Abstract][Full Text] [Related]
10. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair. Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141 [TBL] [Abstract][Full Text] [Related]
11. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
13. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Yamini B; Yu X; Gillespie GY; Kufe DW; Weichselbaum RR Cancer Res; 2004 Sep; 64(18):6381-4. PubMed ID: 15374943 [TBL] [Abstract][Full Text] [Related]
14. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314 [TBL] [Abstract][Full Text] [Related]
15. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630 [TBL] [Abstract][Full Text] [Related]
17. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Gilbert CA; Daou MC; Moser RP; Ross AH Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377 [TBL] [Abstract][Full Text] [Related]
18. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Huang TT; Hlavaty J; Ostertag D; Espinoza FL; Martin B; Petznek H; Rodriguez-Aguirre M; Ibañez CE; Kasahara N; Gunzburg W; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM Cancer Gene Ther; 2013 Oct; 20(10):544-51. PubMed ID: 23969884 [TBL] [Abstract][Full Text] [Related]
19. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. Montaldi AP; Godoy PR; Sakamoto-Hojo ET Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369 [TBL] [Abstract][Full Text] [Related]
20. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]